Research Topics
| Charles M BeasleySummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapineChristopher D Carlson
Eli Lilly and Company, Indianapolis, Ind, USA
J Clin Psychiatry 64:898-906. 2003..040) and significantly shorter among clozapine-treated patients (p =.021). CONCLUSION: This analysis of available data from olanzapine clinical trials lends additional support to olanzapine's favorable EPS profile...- The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT intervalCharles M Beasley
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
J Am Coll Cardiol 46:678-87. 2005..This study was designed to evaluate effects of tadalafil, a phosphodiesterase-5 inhibitor used for the treatment of erectile dysfunction (ED), on the QT interval... - Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditionsCharles M Beasley
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
Pacing Clin Electrophysiol 34:1116-27. 2011..However, little is known about systematic changes in the QTc across contiguous days when normal volunteers are brought into a controlled inpatient environment... - Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trialsCharles M Beasley
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
J Clin Psychopharmacol 27:682-6. 2007..05 vs placebo). Data sources were differentially sensitive in detecting changes in suicidal ideation and behaviors. Fluoxetine treatment led to greater benefit rather than risk for suicidality... - All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysisCharles M Beasley
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 27:252-8. 2007..This integrated analysis compared the likelihood of discontinuation from olanzapine treatment versus other antipsychotics among patients with schizophrenia... - A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapseCharles M Beasley
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 1730, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 23:582-94. 2003..In remitted stabilized patients with schizophrenia or schizoaffective disorder, olanzapine demonstrated a positive benefit-to-risk profile in relapse prevention... - Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patientsStacy R Lindborg
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center DC 6324, 46285, Indianapolis, IN, USA
Psychiatry Res 119:113-23. 2003..These data suggest that IM olanzapine has a favorable QTc interval profile in acutely agitated patients with schizophrenia, bipolar mania, or dementia... - Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Charles M Beasley
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 26:40-4. 2006.... - Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorderSitra Tauscher-Wisniewski
Eli Lilly and Company, Indianapolis, IN 46285, USA
Psychol Med 37:1585-93. 2007.... - Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trialsIlya Lipkovich
Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA
Psychopharmacol Bull 42:23-39. 2009..These results confirm that cut-offs for weight gain during the first 4 weeks of treatment may be useful in evaluating SWG risk for an individual patient... - Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafilR Dustan Sarazan
Lilly Research Laboratories, Eli Lilly and Company, 2001 W Main St, Greenfield, Indianapolis, IN 46140, USA
Eur J Pharmacol 502:163-7. 2004..None of the three compounds was a potent blocker of the HERG channel... - Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placeboMargaret O Sowell
Lilly Research Laboratories, Eli Lilly and Co, Corporate Center, Drop Code 1758, Indianapolis, IN 46285, USA
J Clin Endocrinol Metab 87:2918-23. 2002..The results of this study do not support the hypothesis that olanzapine or risperidone directly impair pancreatic beta-cell function... - Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementiaKarena M Meehan
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Neuropsychopharmacology 26:494-504. 2002..Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation... - Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trialsBrian A Millen
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
J Psychopharmacol 25:639-45. 2011..Potential consequences of weight gain should be considered prior to starting olanzapine. Olanzapine-treated patients should receive regular weight monitoring... - Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatmentDavid J Brunswick
The Depression Research Unit, University of Pennsylvania Medical Center, University Science Center, 8th Floor, 3600 Market Street, Philadelphia, PA 19104, USA
J Affect Disord 68:243-9. 2002..The purpose of this study was to investigate the relationship between steady-state plasma drug concentrations and outcome during relapse-prevention therapy with fluoxetine... - Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implicationsCristina Cusin
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 68:52-7. 2007..While patterns of response have been examined as possible predictors of outcome, the clinical correlates and implications of early worsening per se have not been investigated... - Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodesRoy H Perlis
Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Psychother Psychosom 76:40-6. 2007..The time course and clinical correlates of this phenomenon have not been characterized in detail... - Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysisWilliam J Crumb
Department of Pediatrics (Cardiology, Tulane University School of Medicine, New Orleans, Lousiana, USA
Pharm Res 23:1133-43. 2006..CONCLUSION: The antipsychotics do not inhibit the ion channels I(to), I(Na), I(sus), I(K1) to any appreciable extent; however, blockade of hERG is a likely mechanism for the prolongation of the QT interval... - Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trialSerge Carrier
Department of Urology, Jewish General Hospital, 3755 Côte Sainte Catherine E 210, Montreal, Quebec, Canada H3T 1E2
J Sex Med 2:685-98. 2005..Erectile dysfunction (ED) is a highly prevalent, often undertreated condition... - Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidolToshiya Inada
National Center of Neurology and Psychiatry, Japan
Int Clin Psychopharmacol 18:39-48. 2003..This preliminary and retrospective work suggests that the DIEPSS can be used to operationally define the presence or absence, and make the clinical diagnosis, of specific EPS syndromes... - Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trialJay M Young
South Orange County Medical Research Center, 24301 Paseo de Valencia, Suite 100 Laguna Woods, CA 92653, USA
J Androl 26:310-8. 2005..The most common treatment-emergent adverse events were headache, back pain, dyspepsia, and nasopharyngitis. Both 10- and 20-mg tadalafil improved erectile function for up to 36 hours postdosing in men with ED of varied severity... - A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafilAlexander von Keitz
Urology Practice, AM Krummbogen 15, 35039 Marburg, Germany
Eur Urol 45:499-507; discussion 507-9. 2004.... - Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormonesWayne J G Hellstrom
Department of Urology SL 42, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
J Urol 170:887-91. 2003..We assessed the effects on spermatogenesis of placebo vs 10 or 20 mg tadalafil administered daily for 6 months to healthy men and men with mild erectile dysfunction...